Century Therapeutics (IPSC) Stock Price, Quote, News & History | Benzinga

Century Therapeutics Inc (IPSC) Stock Price, Quote, News & History

IPSCNASDAQ

Trade with Public

Trade with Public

$2.02

-0.0041-0.2%

Last update: Aug 31, 3:22 PM

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$2.00

Close

-

Volume / Avg.

217.83K / 1.16M

Day Range

$1.97 - $2.05

52 Wk Range

0.44 - 3.04

Market Cap

$365.94M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

48

Short Interest

16.34%

Days to Cover

51.17

Recent Century Therapeutics, Inc. News

Concentrix Reports Downbeat Q2 Earnings, Joins Nuvectis Pharma, Vishay Intertechnology And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session

US stock futures up, Dow futures gain 100+ points. Concentrix Corp (CNXC) shares down 24% after weak Q2 results and lowered FY26 guidance. Other stocks also decline in pre-market trading.

Avi Kapoor

Apogee Enterprises Posts Strong Q1 Earnings, Joins ACADIA Pharmaceuticals, Crocs And Other Big Stocks Moving Higher On Friday

Apogee Enterprises Inc (NASDAQ: APOG) rose sharply after the company reported better-than-expected first-quarter financial results. Other big gainers in today's session include FuelCell Energy Inc (NASDAQ: FCEL) up 17.6%, BitVentures Limited (NASDAQ: BVC) up 14.1%, and ACADIA Pharmaceuticals Inc (NASDAQ: ACAD) up 10.3% after receiving a positive recommendation for a market authorization in Europe.

Avi Kapoor

Graham, Appian And Other Big Stocks Moving Lower In Monday's Pre-Market Session

U.S. stock futures rise, Nasdaq up 1%. Graham Corp shares down 8.7%. Other stocks declining in pre-market trading: BVC, TLK, INDP, APPN, WIX, KB, SSSS, IPSC, AMPL, ICCM, SBSW, ROMA.

Avi Kapoor

Abercrombie & Fitch Upbeat Q1 Earnings, Joins Digital Turbine, Dycom Industries And Other Big Stocks Moving Higher On Wednesday

Dow Jones up 300 points with gains from Abercrombie & Fitch, Digital Turbine, Dycom Industries, Qfin Holdings, Editas Medicine, and others.

Avi Kapoor

This GE Aerospace Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

Top Wall Street analysts changed outlook on top names. See analyst ratings page for upgrades, downgrades, and initiations. Check out what analysts think of GE stock.

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-86.76M

Investing Cash Flow (TTM)

-47.82M

Financing Cash Flow (TTM)

126.99M

Free Cash Flow (TTM)

-88.09M

Capital Expenditure (TTM)

-1.33M

Net Change in Cash (TTM)

-7.59M

Analyst Trends and Forecast

1

Apr

1

May

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.6

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$285.63M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

1.58

Earnings Yield % (TTM)

-45.93%

Earnings Yield % (FWD)

-25.19%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$1.28

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$49.64M

Debt to Equity

0.17

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$2.00

Close

-

Volume / Avg.

217.83K / 1.16M

Day Range

$1.97 - $2.05

52 Wk Range

0.44 - 3.04

Market Cap

$365.94M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

48

Short Interest

16.34%

Days to Cover

51.17

About

Sector

Health Care

Industry

Biotechnology

Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its b...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Century Therapeutics (IPSC) stock?

A

You can purchase shares of Century Therapeutics (NASDAQ:IPSC) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Century Therapeutics (IPSC) competitors?

A

Other companies in Century Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for Century Therapeutics (IPSC) stock?

A

Century Therapeutics has a consensus price target of $7.29.

Q

What is the current price for Century Therapeutics (IPSC)?

A

The stock price for Century Therapeutics (NASDAQ: IPSC) is $2.0209 last updated August 31, 2026 at 3:22 PM EDT.

Q

Does Century Therapeutics (IPSC) pay a dividend?

A

There are no upcoming dividends for Century Therapeutics.

Q

When is Century Therapeutics (NASDAQ:IPSC) reporting earnings?

A

Century Therapeutics does not have any upcoming earnings scheduled.

Q

Is Century Therapeutics (IPSC) going to split?

A

There is no upcoming split for Century Therapeutics.

Q

What sector and industry does Century Therapeutics (IPSC) operate in?

A

Century Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.